|
|
 |
|
Viewing report
|
|
|
|
Partneringwith Bigpharma: The Definitive Guide to Partnering Interests, Contacts & Agreements
CurrentPartnering, July 2008, Pages: 648
This report provides the most comprehensive and in-depth insight into the business development, licensing and partnering interests and activity of the worlds leading fifty biopharma companies, providing all the information you require to better understand bigpharma partnering.
One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 200 charts allow quick understanding of each bigpharma companies dealmaking trends over the last four years.
This report contains over 1,200 links to online copies of actual contract documents as submitted to the Securities Exchange Commission by bigpharma and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
Key benefits:
Partnering with Bigpharma provides the user with the following key benefits:
- Detailed company profiles for each of the top 50 bigpharma companies
- Over 200 charts showing a company’s dealmaking activity since 2005, allowing quick identification potential partners
- In-depth marketed and pipeline product activity of each company
- Partnering interests and therapy focus revealed
- Partnering activity since 2000 – number of deals per year
- Partnering activity for 2005-2008
- Activity by deal type
- Activity by phase of development
- Activity by therapeutic area
- List of recent partner companies
- Comprehensive access to over 1,200 actual contracts entered into by the leading fifty biopharma companies*
- Insight into the terms included in a partnering agreement, together with real world clause examples
- Understand the key deal terms the company has agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
*Subject to being published via regulatory requirements of the Securities Exchange Commission.
Report scope:
Partnering with Bigpharma is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the leading fifty biopharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s approach to partnering.
Partnering with Bigpharma includes:
Detailed company profiles for each of the top 50 bigpharma companies, including:
- Full contact details
- Business developer contact details including name, title, email and telephone (where available)
- Marketed indications
- Pipeline indications
- Partnering interests and indications
- Partnering activity since 2000
- Current partner companies since 2005
Partnering activity since 2005 by:
- Deal type
- Stage of development
- Therapy area
- Over 200 charts showing the dealmaking activity of each company since 2005
- The tools to enable effective and efficient preparation for partnering negotiation with bigpharma
- Listing of over 1,200 contract documents between bigpharma and partner companies
- The leading M&A and partnering deals by value 2005-8
- Most active M&A and partnering dealmakers 2005-8
The Partnering with Bigpharma report also provides comprehensive access to available contract documents for each of the fifty bigpharma companies. Analyzing actual company agreements allows assessment of the following:
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal? How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subscontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
For each company in Partnering with Bigpharma report, the available contracts are listed by deal type, including:
- Co-development
- Co-marketing
- Co-promotion
- Collaborative R&D
- Development
- Distribution
- Joint venture
- Licensing
- M&A
- Manufacturing
- Marketing
- Promotion
- Research
- Supply
Customers who bought this item also bought
Partneringwith Bigpharma: The Definitive Guide to Partnering Interests, Contacts & Agreements
Bigpharma Partnering Agreements
Clinical Stage Partnering Agreements in Biopharma
Strategies and Tactics for Successful Partnering
Late Stage Deals: Strategy, Structure and Payment Terms
Early Stage and Discovery Deals: Strategy, Structure and Payment Terms, 2nd Edition
Dainippon Sumitomo Dealmaking Profile 2007
Watson Pharmaceuticals Inc Deals Briefing
|
|
|
|
